Hormonal
Semaglutide 2.4 mg/week administered as an add-on to hospital-based non-pharmacological obesity care significantly reduces adiposity (BMI) in young adults (18-28 years) with childhood-onset obesity who have demonstrated low or medium treatment response to prior behavioral interventions.
For young adults with obesity who have not lost enough weight through standard diet and exercise programs, adding weekly semaglutide (2.4 mg) to their existing care plan is a clinically validated strategy to further reduce body mass index. The treatment involves a gradual dose increase over 16 weeks to minimize side effects, followed by 52 weeks of maintenance, all while continuing behavioral counseling.
We hypothesise that treatment with a GLP-1 RA, as an add-on to hospital-based non-pharmacological obesity care, will reduce adiposity in youth with childhood-onset obesity and insufficient treatment response to hospital-based obesity care alone.
Why this rating
This is a study protocol for a randomized, double-blinded, placebo-controlled trial, which is the highest level of evidence design, although results are not yet published.
Source
Protocol for a randomised, double-blinded, controlled trial of youth with childhood-onset obesity treated with semaglutide 2.4 mg/week: the RESETTLE trial
Sarah Byberg et al. · BMJ Open · 2024
DOI 10.1136/bmjopen-2023-082446
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →